Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities
2018-01-25
FDA-2017-D-6592
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities January 2018
I. Introduction
The purpose of this document is to state the Food and Drug Administration’s (FDA’s) intent to exercise enforcement discretion regarding application of the regulation on foreign supplier verification programs (FSVPs) to importers of grains imported into the United States as raw agricultural commodities (RACs). For the reasons stated below, we intend to exercise enforcement discretion with respect to the FSVP regulation for importers of grain RACs that are solely engaged in the storage of grain intended for further distribution or processing and grain importers that do not take physical possession of the grain they import but instead arrange for the delivery of the grain to others for storage, packing, or manufacturing/processing (such as certain commodity brokers with respect to the FSVP regulation).
We are issuing this guidance consistent with our good guidance practices (GGP) regulation (21 CFR 10.115). This guidance is immediately effective because FDA has determined that prior public participation is not feasible or appropriate (21 CFR 10.115(g)(2)).
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
This guidance provides information to facilitate understanding of the applicability of the FSVP requirements to the importation of grain RACs. The pronouns “I,” “me,” and “you” are used in this guidance to refer to the importer. “Agency” and the pronouns “we” and “our” are used to refer to FDA.
II. Background
Many RACs that are not fruits or vegetables, including grains, are imported into the United States. Grain RACs imported into the United States include barley, dent- and flint-corn, sorghum, oats, rice, rye, wheat, amaranth, quinoa, buckwheat, and oilseeds for oil extraction (e.g., cotton seed, flax seed, rapeseed, soybean, sunflower seed).
Mycotoxin contamination is one of the primary hazards associated with grain RACs. Some grains may also contain other hazards, including microbial pathogens such as Salmonella. Grains in which microbial pathogens may be present are usually destined for further processing (for example, extraction of oil from oilseeds and cooking of rice) such that these hazards are controlled. Most grains are dried in the field (rice being the exception, being dried following harvest) and then stored dry, typically in grain elevators, under conditions that minimize fungal growth and mycotoxin production. Although some controls for mycotoxins in grain crops can be applied during cultivation, mycotoxins generally cannot be fully controlled on the farm. Therefore, other post-harvest mitigation measures are employed. These measures include moisture and temperature controls to prevent fungal growth and mycotoxin production; sorting to remove moldy, discolored, and damaged kernels; and milling grains. Sampling and analytical testing are used as a means of segregating lots with higher and lower mycotoxin concentration as appropriate for specific uses. In the United States, most food facilities have programs for mycotoxin control in domestic and imported grains, such as safe practices for storage, drying, sorting, and testing of grain. These programs result in low concentrations of mycotoxins in finished grain-based foods.
The importation of grain RACs into the United States is subject to certain supplier verification requirements established in the FDA Food Safety Modernization Act (FSMA) (Pub. L. 111-353). FSMA amended the Federal Food, Drug, and Cosmetic Act (FD&C Act) to add, among other food safety requirements, provisions requiring the verification of the safety of food imported from foreign suppliers of that food.
Section 805(c) of the FD&C Act directs FDA to issue regulations on the content of FSVPs. We issued the FSVP final rule on November 27, 2015 (80 FR 74225). The FSVP regulation requires food importers to develop, maintain, and follow an FSVP that provides adequate assurances that the foreign supplier uses processes and procedures that provide the same level of public health protection as those required under the preventive controls and produce safety provisions of FSMA (if applicable) and regulations implementing those provisions, as well as assurances that the imported food is not adulterated and that human food is not misbranded with respect to allergen labeling (21 CFR 1.502(a)). Among other things, the FSVP regulation (21 CFR 1.500-1.514) requires most food importers to do the following:
- Analyze the hazards for the foods they import (21 CFR 1.504);
- Evaluate the performance of their potential foreign suppliers and the risk posed by the foods to be imported (21 CFR 1.505); and
- Determine and conduct appropriate foreign supplier verification activities, such as onsite auditing of foreign suppliers, sampling and testing, and review of supplier food safety records (21 CFR 1.506).
The FSVP regulation applies (with certain exceptions) to the importation of “food” as defined in section 201(f) of the FD&C Act (except that “food” for FSVP purposes does not include pesticides as defined in 7 U.S.C. 136(u)) (see 21 CFR 1.500). Thus, the FSVP regulation applies to importers of RACs, including RACs that are grains.
FSMA also includes provisions (codified in section 418 of the FD&C Act) requiring certain food facilities to implement preventive controls to, among other things, provide assurances that hazards identified in a hazard analysis will be significantly minimized or prevented. The preventive controls provisions of FSMA include supplier verification activities as one type of procedure, practice, or process that food facilities might need to use as a preventive control to significantly minimize or prevent hazards arising in the manufacture, processing, packing, or holding of food (section 418(o)(3)(G) of the FD&C Act). FDA’s final rules on current good manufacturing practice (CGMP), hazard analysis, and risk-based preventive controls for human food (80 FR 55908, September 17, 2015) and for animal food (80 FR 56170, September 17, 2015) include provisions requiring receiving facilities to conduct a hazard analysis and to establish and implement supply-chain programs for domestic and imported raw materials and other ingredients for which the facility has identified a hazard requiring a supply-chain-applied control (21 CFR part 117, subpart G, and 21 CFR part 507, subpart E, respectively).
Under the supply-chain program provisions of the preventive controls regulations, a “receiving facility” is a facility subject to the preventive controls and supply-chain program requirements and that manufactures/processes a raw material or other ingredient it receives from a supplier (21 CFR 117.3 and 507.3). A “supply-chain-applied control” is a preventive control for a hazard in a raw material or other ingredient when the hazard is controlled before its receipt (21 CFR 117.3 and 507.3). The supply-chain program requirements include, among other things, determining and conducting appropriate supplier verification activities (such as onsite auditing, sampling and testing, and review of supplier food safety records) to provide assurance that hazards requiring a supply-chain-applied control have been significantly minimized or prevented. Importers of grain RACs that manufacture/process the grain are subject to the preventive controls requirements, including the supply-chain program provisions. In addition, under 21 CFR 1.502(c), grain RAC importers that are also receiving facilities subject to the preventive controls regulations for human or animal food will be deemed in compliance with most of the FSVP requirements when they implement preventive controls for the hazards in the grain in accordance with 21 CFR 117.135 (for human food) or 507.34 (for animal food).
The preventive controls requirements, including the supply-chain program provisions, do not apply to facilities that are solely engaged in the storage of non-produce RACs (including grain RACs) intended for further distribution or processing (21 CFR 117.5(j) and 507.5(g)). This exemption reflects the Agency’s finding that outbreaks of foodborne illness have not been traced back to storage facilities solely engaged in the storage of non-produce RACs (see 78 FR 3646 at 3709, January 16, 2013 and 78 FR 64736 at 64764, October 29, 2013). Consequently, we concluded that subjecting facilities that only store non-produce RACs intended for further distribution or processing to the preventive controls requirements would provide no significant public health benefit.
However, as stated above, the FSVP regulation applies to all importers of non-produce RACs, including importers that are solely engaged in the storage of these RACs intended for further processing. Unless exempt from FSVP (under other provisions) or importing the grain under modified FSVP requirements (e.g., for very small importers), importers of grain RACs such as grain elevators, brokers, and manufacturers/processors may be required to conduct the standard FSVP activities, including evaluating and approving a foreign supplier (21 CFR 1.505) and conducting foreign supplier verification activities (21 CFR 1.506).[1] However, as discussed above, suppliers of grain RACs (i.e., farmers) generally do not control the hazards in the grain. Therefore, the standard FSVP requirements to evaluate potential foreign suppliers and conduct verification of the suppliers generally would not apply to importers of grain RACs.
Rather than the standard FSVP requirements, certain modified requirements would apply when there is a hazard in the grain and either of the following is applicable:
- The grain cannot be consumed without application of an appropriate control (e.g., soybeans, which require heat treatment to denature a natural toxin found in soybeans) (see 21 CFR 1.507(a)(1)). The importer would need to document its determination that the grain cannot be consumed without application of a control.
- The importer’s customer or a subsequent entity will control the hazards in the grain. In such cases, the importer would need to disclose that the grain had not been processed to control the identified hazards and obtain written assurance from the customer that the customer or some subsequent entity will control the hazards (see 21 CFR 1.507(a)(2)-(4)). (We have issued guidance for industry entitled “Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and/or Foreign Supplier Verification Programs” stating we are exercising enforcement discretion with regard to the written assurance requirements to complete rulemaking to address feasibility concerns with the provision (83 FR 598, January 5, 2018).)
III. Discussion
To better align the FSVP regulation with the exemption from preventive controls requirements for facilities solely engaged in the storage of non-produce RACs, and because of the nature of the hazards associated with grain RACs and how they are generally addressed in the distribution chain, we intend to exercise enforcement discretion for importers of grain RACs that are solely engaged in the storage of grain intended for further distribution or processing (in accordance with 21 CFR 117.5(j) or 507.5(g)) with respect to the FSVP regulation. This means that we will not expect these FSVP importers of grain RACs (i.e., grain elevators and other facilities solely engaged in the storage of grain RACs intended for further distribution or processing) to meet any of the FSVP requirements. However, these grain RAC importers remain subject to the statutory prohibition against the introduction or delivery for introduction into interstate commerce of adulterated food (section 301(a) of the FD&C Act (21 U.S.C. 331(a)).
This intent to exercise enforcement discretion with respect to the FSVP regulation also applies to grain importers that do not take physical possession of the grain they import but instead arrange for the delivery of the grain to others for storage, packing or manufacturing/processing (such as certain commodity brokers). Thus, if a firm that is the FSVP “importer” (as defined in 21 CFR 1.500) of a grain RAC arranges for the distribution of the grain without taking physical possession of it (e.g., does not engage in storage, packing, or processing of the grain), we intend to exercise enforcement discretion for the FSVP requirements.
This intent to exercise enforcement discretion with respect to the FSVP regulation for certain importers of grain RACs does not apply to importers that manufacture/process grain RACs. However, as discussed above, we do not expect FSVP to pose a regulatory burden for these manufacturers/processors, because of the nature of the hazards in grain RACs and specific provisions already included in the preventive controls regulations for human or animal food requiring manufacturers/processors to control the hazards that are identified as requiring a preventive control. The only FSVP requirement that the importer that manufactures/processes grain RACs and is also a receiving facility will need to meet is to ensure that it is identified as the FSVP importer of the grain at U.S. entry (in accordance with 21 CFR 1.509). Those importers that manufacture/process grain RACs and are not receiving facilities will likely be able to use the modified provisions in 21 CFR 1.507 rather than perform supplier verification activities.
When a food product under FDA oversight is offered for entry into the United States, the U.S. Customs and Border Protection (CBP) Automated Commercial Environment (ACE) system will prompt the filer to transmit an entity role code or affirmation of compliance code related to FSVP. The entity role code “FSV” indicates that the entry line is subject to the FSVP regulation and currently subject to FSVP enforcement, so the importer must provide its name, electronic mail address, and unique facility identifier recognized as acceptable by FDA (see 21 CFR 1.509). If the food entry line is exempt from the requirements of the FSVP regulation, not yet subject to the regulation, or eligible for enforcement discretion with respect to the FSVP regulation, the filer should transmit the applicable Affirmation of Compliance code. “FSX” should be used if FDA has provided guidance that the agency intends to exercise enforcement discretion for the relevant shipment with respect to the FSVP regulation.
Therefore, importers of grain RACs that are solely engaged in the storage of grain intended for further distribution or processing and grain importers that do not take physical possession of the grain they import but instead arrange for the delivery of the grain to others for storage, packing, or manufacturing/processing should transmit the affirmation of compliance code “FSX” when making entry in the U.S. For more information on importer identification, consult “Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs Regulation,” available at https://www.fda.gov/Food/GuidanceRegulation/FSMA/ucm556661.htm.
This guidance represents the current thinking of the Food and Drug Administration (FDA, the Agency, or we) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.
Related Information
[1] Other FSVP requirements include, but are not limited to, determining whether there are any hazards requiring a control in imported foods (21 CFR 1.504), taking corrective actions (when appropriate) (21 CFR 1.508), ensuring that the importer is identified at U.S. entry (21 CFR 1.509), and recordkeeping (21 CFR 1.510).
Submit Comments
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2017-D-6592.
最新政策法规资讯
-
摩熵医药2026-06-17
-
摩熵医药2026-06-09
-
赛柏蓝2026-06-01
-
深蓝观2026-05-22
-
赛柏蓝2026-04-24
-
摩熵医械2026-01-28
-
摩熵医械2026-01-13
-
摩熵医械2025-12-19
-
赛柏蓝2025-12-12
-
摩熵医械2025-11-28
热门政策标签
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-10-14
-
2026-10-14
-
摩熵咨询 35 78
-
摩熵咨询 28 65
-
颁布机构:国家市场监督管理总局 2026-09-30
-
颁布机构:国家市场监督管理总局 2026-09-29
最新指导原则
-
国家药监局器审中心关于发布<人表皮生长因子受体2基因扩增检测试剂(荧光原位杂交法)注册审查指导原则(2026年修订版)>等2项注册审查指导原则的通告(2026年第28号)
2026-10-13
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
国家药监局器审中心关于发布有源植入式医疗器械电池注册审查指导原则的通告(2026年第27号)
2026-10-08
-
国家药监局器审中心关于发布腹腔内窥镜手术系统注册审查指导原则 第5部分:患者模型试验研究>的通告(2026年第26号)
2026-09-28
-
国家药监局综合司公开征求<医疗器械生产质量管理规范无菌医疗器械检查指导原则(征求意见稿)>等意见
2026-09-24
-
关于公开征求ich<e14/s7b:问答:致qt/qtc 间期延长及潜在致心律失常作用的临床和非临床评价问答>指导原则问答文件实施建议和中文翻译稿意见的通知
2026-09-24
-
国家药监局药审中心关于发布<药物临床试验计算机化系统和电子数据指导原则>的通告
2026-09-22
-
国家药监局药审中心关于发布<化学仿制药滴眼剂研究技术指导原则>和<化学仿制药特殊滴眼剂研究技术指导原则>的通告
2026-09-02
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
国家卫生健康委办公厅关于印发医疗机构卒中中心建设与管理指导原则(2026年版)的通知
2026-07-28
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-10-15
-
2026-10-15
-
2026-10-15
-
摩熵咨询 33 34
-
摩熵咨询 20 8
-
摩熵咨询 20 12
-
颁布机构:国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构:国家药品监督管理局 2026-09-10
-
颁布机构:四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
同部门最新指导原则
-
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
2024-11-15
-
Guidance for Industry: FDA's Voluntary Qualified Importer Program
2024-11-14
-
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24)
2024-11-01
-
Study Data Technical Conformance Guide - Technical Specifications Document
2024-10-31
-
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
2024-10-30
-
CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients
2024-10-24
-
Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination
2024-10-22
-
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling
2024-10-21
-
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA
2024-10-17
-
Postoperative Nausea and Vomiting: Developing Drugs for Prevention
2024-10-17
-
Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method
2024-10-17
-
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development: Guidance for Industry
2024-10-17
-
Core Patient-Reported Outcomes in Cancer Clinical Trials: Guidance for Industry
2024-10-17
-
Requests for Reconsideration at the Division Level Under GDUFA
2024-10-16
-
CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food
2024-10-15
同地域最新指导原则
-
questions and answers on biosimilar development and the bpci act: guidance for industry(生物类似药开发与<生物制品价格竞争与创新法案>问答:行业指南)
2026-10-09
-
postapproval manufacturing changes to biosimilar and interchangeable biosimilar products: questions and answers(生物类似药和可互换生物类似药产品的批准后生产变更:问答)
2026-10-09
-
determining whether to submit an anda or a 505(b)(2) application(确定是提交仿制药申请(anda)还是505(b)(2)申请)
2026-08-17
-
cvm gfi #260 - type vii veterinary master file for research and development and risk reviews(cvm行业指南第260号——用于研发与风险审查的vii型兽药主文件)
2026-08-14
-
container closure systems for human drugs and biological products(人用药品和生物制品的容器密闭系统)
2026-08-13
-
formal meetings between the fda and sponsors or applicants of pdufa products(关于fda与处方药使用者付费法案(pdufa)产品申办方或申请人之间正式会议的指南)
2026-08-12
-
hemodialysis blood tubing sets - premarket notification (510(k)) submissions: guidance for industry and food and drug administration staff(血液透析血液管路套装 - 上市前通知(510(k))申报资料:行业和食品药品监督管理局工作人员指南)
2026-07-23
-
opioid analgesic drugs: considerations for benefit-risk assessment framework(阿片类镇痛药:效益-风险评估框架的考量)
2026-05-13
-
development of non-opioid analgesics for acute pain(急性疼痛的非阿片类镇痛药开发)
2026-05-13
-
development of local anesthetic drug products with prolonged duration of effect(延长作用时间的局部麻醉药品的开发)
2026-05-13
-
stimulant use disorders: developing drugs for treatment(兴奋剂使用障碍:治疗药物的开发)
2026-05-13
-
development of non-opioid analgesics for chronic pain(慢性疼痛非阿片类镇痛药的开发)
2026-05-13
-
pulmonary tuberculosis: developing drugs for treatment(肺结核:治疗药物的开发)
2026-05-08
-
clostridioides difficile infection: developing drugs for treatment, reduction of recurrence, and prevention(艰难梭菌感染:用于治疗、减少复发及预防的药物开发)
2026-05-08
-
enforcement priorities for certain new tobacco products marketed without premarket authorization(未经上市前授权销售的某些新烟草产品的执法重点)
2026-05-08

